Areas of interest
Areas of Licensing and Partnering
Prescription Medicines, Consumer Health Care and Animal Health are areas in which Boehringer Ingelheim seeks international Licensing and Partnering opportunities based on innovation and therapeutic progress.
The primary focus is on therapeutic areas where Boehringer Ingelheim has proven expertise and a track record in development, registration and marketing, as well as in-house research programmes with potential for partnering opportunities.
- Cardiovascular diseases
- Central nervous system (CNS) disorders
- Immunology
- Metabolic diseases
- Oncology
- Respiratory diseases
- Urology
- Virology
- Breakthrough innovations in other areas
More information
Contact us
Are you interested in arranging an appointment with Boehringer Ingelheim experts during the exhibition? Need more information?
Send us an e-mail.
The Consumer Health Care business is a core business of the Boehringer Ingelheim Corporation. We concentrate our Licensing and Partnering efforts on:
- Cough & Cold
- Gastrointestinal
- Vein therapeutics
- Innovations in other areas
- Rx to OTC switch opportunities
More information on Consumer Health Care.
Contact us
Are you interested in arranging an appointment with Boehringer Ingelheim experts during the exhibition? Need more information?
Cough & Cold
Phone: + 49 / 6132 / 77 3374
Vein therapeutics, Menstrual pain, Gastrointestinal
Phone: + 49 / 6132 / 77 92576
Innovations in other areas and Rx to OTC switch opportunities
Phone: + 49 / 6132 / 77 6943
Or send us an e-mail.
Boehringer Ingelheim has a wide range of veterinary products covering:
- Biologicals
- Pharmaceuticals
- Natural Care
Our core segments are:
- food-producing animals (swine and cattle)
- companion animals (small animals and horses).
More information on Animal Health.
Contact us
You would like to arrange an appointment with Boehringer Ingelheim experts during an exhibition?
You are interested in out-licensing your innovative product?
You are looking for a successful research collaboration?
Send us an e-mail.
